Logo

Swift Biosciences Accel-Amplicon Plus Cancer NGS Panels

Apr 23, 2018

Swift Biosciences has launched a suite of nine tumor-specific gene panels using its Accel-Amplicon technology. The Accel-Amplicon Plus Cancer NGS Panels enable detection of SNVs, copy number variants, and small indels. The company has launched four disease-focused panels for colorectal cancer, Lynch syndrome, lung cancer, and myeloid malignancies. In addition, it has also launched five gene panels, including one that focuses on comprehensive coverage of the TP53 gene, two BRCA-focused panels, an EGFR panel, and a pan-cancer panel. The panels are compatible with Illumina's sequencing instruments. Just 10 nanograms of sample input are required, and sample inputs can include DNA from formalin-fixed paraffin-embedded tissue and fine needle aspirates, as well as cell-free DNA. In addition, Swift has also launched its Swift Bioinformatics Resources, which include both open source and commercial bioinformatics tools to analyze NGS data.

Breaking News
The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.